Anaphylactic shock following povidone.
OBJECTIVE
To report a patient with an anaphylactic reaction related to povidone administration.


METHODS
A 37-year-old man with a history of allergic rhinitis presented with urticaria, dyspnea, wheezing, rhinorrhea, and dysphonia 20 minutes after the intraarticular administration of mepivacaine hydrochloride and paramethasone acetate in his right knee. Two months after this episode, he was admitted for controlled provocation tests. Tests on mepivacaine were negative. The preparation of paramethasone contained the excipients benzalkonium chloride, polysorbate 80, and povidone. In vitro tests and provocation were negative with polysorbate 80 and benzalkonium chloride, but positive with povidone.


CONCLUSIONS
Povidone, a mixture of synthetic polymers, is commonly used as an excipient in pharmaceutical products, an additive in food products, and a dispersant and stabilizer in hairsprays. Although it is well tolerated when used topically or parenterally, local and systemic effects have been reported. Furthermore, multiorgan involvement resulting from accumulation of the drug in the reticuloendothelial system has been described. The immunologic properties of povidone have not been explored in humans, but have been in animals. In fact, the capacity of povidone to release histamine and its immunogenicity are proportional to its molecular weight. An immunoglobulin (Ig) E-mediated hypersensitivity reaction in asthma has been reported. In our case, povidone was responsible for the syndrome. However, we cannot determine the exact mechanism. An unspecific histamine release and/or an IgE-mediated hypersensitivity could be involved.


CONCLUSIONS
Povidone was responsible for a severe anaphylactic reaction in our patient. The possibility of an iatrogenic adverse effect caused by the excipient but not by the active ingredient should be considered in patients exhibiting similar symptoms. We believe that the excipients used in the preparation of all medicines should be disclosed.
Gonzalo Garijo
M A
MA
University Hospital Infanta Cristina, Badajoz, Spain.
Durán Quintana
J A
JA
Bobadilla González
P
P
Máiquez Asuero
P
P
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007428:Intradermal Tests; D008297:Male; D008619:Mepivacaine / Q000008:administration & dosage / Q000627:therapeutic use; D010248:Paramethasone / Q000008:administration & dosage / Q000627:therapeutic use; D010592:Pharmaceutic Aids / Q000009:adverse effects*; D011205:Povidone / Q000009:adverse effects*; D012221:Rhinitis, Allergic, Perennial / Q000150:complications
D000779:Anesthetics, Local; D000893:Anti-Inflammatory Agents; D010592:Pharmaceutic Aids; D008619:Mepivacaine; D011205:Povidone; D010248:Paramethasone